Innate Pharma Presents Promising Lacutamab Data at ASCO 2025

Innate Pharma SA ( (FR:IPH) ) has shared an update.

Innate Pharma SA announced promising long-term follow-up data from its Phase 2 TELLOMAK clinical trial, highlighting the efficacy of lacutamab in treating Sézary syndrome (SS) and mycosis fungoides (MF), two aggressive forms of CTCL. The data, presented at the ASCO Annual Meeting 2025, showed a global overall response rate of 42.9% for SS and 19.6% for MF, with significant durability of response. Lacutamab’s performance has led to its Breakthrough Therapy Designation by the FDA, supporting its potential as a critical treatment option for patients with limited alternatives.

The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR2.50 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.

More about Innate Pharma SA

Innate Pharma SA is a biotechnology company focused on developing therapeutic antibodies for cancer treatment. The company specializes in innovative immunotherapy solutions, targeting rare and aggressive forms of cancer, such as cutaneous T-cell lymphoma (CTCL).

Average Trading Volume: 128,955

Technical Sentiment Signal: Sell

Current Market Cap: €181.4M

For a thorough assessment of IPH stock, go to TipRanks’ Stock Analysis page.